Relationship between proteinuria, physical activity, and left ventricular hypertrophy in patients with chronic glomerulonephritis

Background: Chronic glomerulonephritis (GN) is a kidney disorder characterized by glomerular inflammation and damage, often triggered by immune-mediated mechanisms and infections. The relationship between proteinuria, physical activity, and left ventricular hypertrophy (LVH) remains unclear. This study aimed to investigate the association between proteinuria and LVH in non-diabetic patients with chronic GN and to assess the impact of physical activity on cardiovascular health. Methods: A total of 165 male chronic GN patients (mean age: 55.65 ± 15.81 years) were compared with 90 age-matched healthy males. Proteinuria was measured using 24-hour quantification (24 h QP). Echocardiographic parameters, including left ventricular ejection fraction (LVEF), left ventricular mass index (LVMI), and LVH, were assessed. Physical activity levels were evaluated using a validated self-reported questionnaire. Results: Proteinuria ≥3.5 g/day (nephrotic range) was observed in 54 (32.7%) patients. Chronic GN patients had significantly higher creatinine, LVMI, and LVH compared to controls. Patients with nephrotic proteinuria exhibited greater LVMI and LVH than those with non-nephrotic proteinuria. A significant association was observed between LVMI and LVH in patients with nephrotic syndrome. Univariate regression analysis showed that increased LVMI and LVH were associated with higher nephrotic proteinuria. Notably, higher physical activity was associated with reduced nephrotic proteinuria and lower for cardiovascular health. Conclusions: LVH was more prevalent among patients with chronic GN, particularly those with nephrotic proteinuria. The findings underscore the importance of physical activity in reducing cardiovascular risks in this population. These results support the integration of tailored exercise programs into the clinical management of chronic kidney disease (CKD) patients.

Chronic glomerulonephritis; Nephrotic proteinuria; Left ventricular mass index; Left ventricular hypertrophy; Physical activity

[1] Yang Y, Tang XF, Wang Y, Xu JZ, Gao PJ, Li Y. High-sensitivity C-reactive protein predicts microalbuminuria progression in essential hypertensive patients: a 3-year follow-up study. Blood Pressure Monitoring. 2024; 29: 242–248.

[2] Sági B, Késői I, Vas T, Csiky B, Nagy J, Kovács TJ. Left ventricular myocardial mass index associated with cardiovascular and renal prognosis in IgA nephropathy. BMC Nephrology. 2022; 23: 285.

[3] Dong T, Wang TKM. Nuances in defining normal ranges for chamber quantification with cardiovascular magnetic resonance. Circulation: Cardiovascular Imaging. 2024; 17: e016488.

[4] Ansari MSHK, Noorani MSS, Fatema A, Shaikh AH. Electrocardiographic and echocardiographic changes in non-hemodialysis chronic kidney disease patients: a cross-sectional study. Perspectives in Medical Research. 2024; 12: 20.

[5] Toriumi S, Hoshide S, Kabutoya T, Kario K. Nighttime blood pressure and glucose control impacts on left ventricular hypertrophy: the Japan Morning Surge Home Blood Pressure (J-HOP) Study. Hypertension Research. 2024; 47: 507–514.

[6] Wernhart S, Rassaf T. Exercise, cancer, and the cardiovascular system: clinical effects and mechanistic insights. Basic Research in Cardiology. 2025; 120: 35–55.

[7] Joseph G, Marott J, Biering-Sørensen T, Johansen M, Saevereid H, Nielsen G, et al. Level of physical activity, left ventricular mass, hypertension, and prognosis. Hypertension. 2019; 75: 693–701.

[8] Li S, Luo J, Zhao S, Zhou H, Xi R, Chen J, et al. Long-term estimated physical activity patterns from youth to middle age and left ventricular structure and function: a 30-year longitudinal study. Journal of the American Heart Association. 2025; 14: e041256.

[9] Hegde S, Solomon S. Influence of physical activity on hypertension and cardiac structure and function. Current Hypertension Reports. 2015; 17: 1–8.

[10] McQuarrie EP, Patel RK, Mark PB, Delles C, Connell J, Dargie HJ, et al. Association between proteinuria and left ventricular mass index: a cardiac MRI study in patients with chronic kidney disease. Nephrology Dialysis Transplantation. 2010; 26: 933–938.

[11] Moreira JBN, Wohlwend M, Wisløff U. Exercise and cardiac health: physiological and molecular insights. Nature Metabolism. 2020; 2: 829–839.

[12] Lak M, Divsalar F, Charmduzi F, Soltani SR, Reza M. Evaluation of the relationship between neurological and cardiovascular diseases in adults and children with infection and HTN based on pharmacological points. International Neurourology Journal. 2024; 28: 821–832.

[13] Tanmoy SA, Das A. Relation between hypertensive retinopathy with left ventricular hypertrophy and proteinuria in hypertensive patient. European Journal of Medical and Health Research. 2025; 3: 145–154.

[14] Mancusi C, Basile C, Gerdts E, Fucile I, Manzi MV, Lembo M, et al. Carotid plaque offsets sex-related differences in cardiovascular risk of young hypertensive patients. European Journal of Internal Medicine. 2024; 130: 137–143.

[15] Araujo RH, Werneck AO, Weaver RG, Tassitano RM, Szwarcwald CL, Jesus GM, et al. No or low moderate-to-vigorous physical activity: focusing on the least active as an additional approach for physical activity surveillance. Journal of Physical Activity and Health. 2024; 21: 536–540.

[16] Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. Annals of Internal Medicine. 1999; 130: 461–470.

[17] Devereux RB, Dahlöf B, Gerdts E, Boman K, Nieminen MS, Papademetriou V, et al. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation. 2004; 110: 1456–1462.

[18] Schroeder AP, Kristensen BO, Nielsen CB, Pedersen EB. Heart function in patients with chronic glomerulonephritis and mildly to moderately impaired renal function. An echocardiographic study. Blood Pressure. 1997; 6: 286–293.

[19] Stefanski A, Schmidt KG, Waldherr R, Ritz E. Early increase in blood pressure and diastolic left ventricular malfunction in patients with glomerulonephritis. Kidney International. 1996; 50: 1321–1326.

[20] Chen J, Tang Y, Zhu M, Lv J, Fu S, He H, et al. Association of echocardiographic parameters with mortality in hospitalized patients with lupus nephritis. Nephrology. 2017; 22: 872–884.

[21] Bhusal KR, Devkota S, Pathak S, Khanal P, Khanal U, Thapalia P, et al. Prevalence of microalbuminuria in non-diabetic hypertensive patients and its correlation with changes in left ventricular and left atrial characteristics. Journal of Nepal Health Research Council. 2023; 20: 838–841.

[22] Al-Sharifi A, Mingher HM. Microalbuminuria and left ventricular hypertrophy in patients with essential hypertension. Journal of the Pakistan Medical Association. 2019; 69: S13–S16.

[23] Wang T, Zhong H, Lian G, Cai X, Gong J, Ye C, et al. Low-grade albuminuria is associated with left ventricular hypertrophy and diastolic dysfunction in patients with hypertension. Kidney and Blood Pressure Research. 2019; 44: 590–603.

[24] Yan S, Yao F, Huang L, Ruan Q, Shen X, Zhang S, et al. Low-grade albuminuria associated with subclinical left ventricular diastolic dysfunction and left ventricular remodeling. Experimental and Clinical Endocrinology & Diabetes. 2015; 123: 515–523.

[25] Salmasi AM, Jepson E, Grenfell A, Kirollos C, Dancy M. The degree of albuminuria is related to left ventricular hypertrophy in hypertensive diabetics and is associated with abnormal left ventricular filling: a pilot study. Angiology. 2003; 54: 671–678.

[26] Wachtell K, Olsen MH, Dahlöf B, Devereux RB, Kjeldsen SE, Nieminen MS, et al. Microalbuminuria in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. Journal of Hypertension. 2002; 20: 405–412.

[27] Nabbaale J, Kibirige D, Ssekasanvu E, Sebatta ES, Kayima J, Lwabi P, et al. Microalbuminuria and left ventricular hypertrophy among newly diagnosed black African hypertensive patients: a cross sectional study from a tertiary hospital in Uganda. BMC Research Notes. 2015; 8: 198.

[28] Murkamilov IT, Aitbaev KA, Sarybaev AS, Fomin VV, Gordeev IG, Rayimzhanov ZR, et al. Relationship of remodeling of carotid arteries and left ventricular geometry in patients with chronic glomerulonephritis. Kardiologiia. 2018; 58: 45–52.

[29] Svenningsen P, Friis UG, Versland JB, Buhl KB, Møller Frederiksen B, Andersen H, et al. Mechanisms of renal NaCl retention in proteinuric disease. Acta Physiologica. 2013; 207: 536–545.

[30] Peters MN, Seliger SL, Christenson RH, Hong-Zohlman SN, Daniels LB, Lima JAC, et al. “Malignant” left ventricular hypertrophy identifies subjects at high risk for progression to asymptomatic left ventricular dysfunction, heart failure, and death: MESA (multi-ethnic study of atherosclerosis). Journal of the American Heart Association. 2018; 7: e006619.

[31] Yang L, Wu X, Wang Y, Wang C, Hu R, Wu Y. Effects of exercise training on proteinuria in adult patients with chronic kidney disease: a systematic review and meta-analysis. BMC Nephrology. 2020; 21: 120.

[32] He YM, Chen WL, Kao TW, Wu LW, Yang HF, Peng TC. Relationship between ideal cardiovascular health and incident proteinuria: a 5-year retrospective cohort study. Nutrients. 2022; 14: 4040.

[33] Picciotto D. Pathophysiology of physical exercise in kidney patients: unveiling new players—the role of myokines. Kidney and Blood Pressure Research. 2024; 49: 457–471.

[34] Currie G, Delles C. Proteinuria and its relation to cardiovascular disease. International Journal of Nephrology and Renovascular Disease. 2013; 6: 121–134.

[35] Eknoyan G, Hostetter T, Bakris GL, Hebert L, Levey AS, Parving HH, et al. Proteinuria and other markers of chronic kidney disease: a position statement of the national kidney foundation (NKF) and the national institute of diabetes and digestive and kidney diseases (NIDDK). American Journal of Kidney Diseases. 2003; 42: 617–622.